AB Science
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, AB Science sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
AB Science: 8 sponsored US clinical trials, 2 recruiting.
AB Science sponsors 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 7 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Myelodysplastic Syndrome/Acute Myeloid Leukemia, with 1 trials.
Upper-quartile sponsor footprint
AB Science sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05211570
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
NCT03127267
Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
NCT01694277
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
NCT01470131
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
NCT01280565
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
NCT00812240
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis
NCT00814073
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
NCT00789633
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 7 |
Where AB Science enrollment is open (later-stage tilt)
2 recruiting of 8 indexed (25% open); 3 completed (38%).
Phase mix: 7 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Myelodysplastic Syndrome/Acute Myeloid Leukemia (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
AB Science: open-pipeline peers nationwide
Peers matched on 8 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
AB Science sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
- Aciex Therapeutics · 8 trials · 0% recruiting
Sponsors near 25% open enrollment (± trial volume)
- Abdul Latif Jameel Poverty Action Lab · 25% recruiting · 4 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
- Advocate Hospital System · 25% recruiting · 4 trials
Related
What to do with this AB Science page
8 registered trials is a research-attention snapshot, not an endorsement of AB Science or any single study.
- 2 of AB Science's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Myelodysplastic Syndrome/Acute Myeloid Leukemia is the condition AB Science studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Myelodysplastic Syndrome/Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
AB Science pipeline card: 8 registered trials from official public datasets.Report a data error.